FibroGen announces data supporting safety and efficacy of FG-3019 in patients with IPF
FibroGen announced the full data set from a clinical study of patients with idiopathic pulmonary fibrosis treated for 48 weeks with the investigational drug FG-3019. In the study lung fibrosis, measured by HRCT, was reduced in a substantial portion of patients who received FG-3019. September 20, 2014